Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Summit Therapeutics to present further data showing ridinilazole's superiority

Summit Therapeutics PLC is to present further data showing the superiority of its new antibiotic for hospital superbug C.Diff over the standard of care medicine. .
Summit Therapeutics to present further data showing ridinilazole's superiority
C. diff is a serious threat in hospitals and care homes and there are between 450,000 and 700,000 cases in the US annually..

Summit Therapeutics PLC (NASDAQ: SMMT, LON: SUMM) is to present further data showing the superiority of its new antibiotic for hospital superbug C.Diff over the standard of care medicine.

The additional data on Summit's ridinilazole versus vancomycin comes from the  from the Phase 2 CoDIFy trial and will be heard at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

Taking the antibiotic ridinilazole resulted in a marked reduction in rates of C-Diff recurrence as compared to vancomycin (14.3% versus 34.8%), the drug discovery firm will say.

This result comes on top of  the previously reported statistical superiority in 'sustained clinical response' rates of ridinilazole over vancomycin (66.7% compared to 42.4%) for treating the disease.

Sustained clinical response is defined as clinical cure at the end of treatment and no recurrence of the condition in 30 days after therapy.

C. diff is a serious threat in hospitals and care homes and there are between 450,000 and 700,000 cases in the US annually.

Recurrence is a key problem as repeat episodes are typically more severe and associated with an increase in mortality rates and healthcare costs.

Summit shares were unchanged in London at 96p each.

Giles_55af4ddca6481.jpg
Why Invest In Summit Therapeutics PLC? Read More Here

Register here to be notified of future SUMM Company articles
View full SUMM profile

Summit Therapeutics PLC Timeline

Related Articles

Cancer
May 02 2016
As UK biotechs are beating a trail to the US craving greater understanding and higher valuation, Doerfler and his team have opted to go in the opposite direction.
Pollen2.jpg
July 13 2016
Updating investors, the company said turnover will be around £48.5mln, representing a rise of 12%, or 19% once the figure is adjusted for currency movements.
drug resistant infections such as E. coli and Pseudomonas
05:50
In vivo testing confirmed that Redx’s novel compounds were highly effective against certain drug resistant strains of bacteria.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.